Graduate School of Engineering, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, 657-8501, Japan.
Innovation Center of Nanomedicine, Kawasaki Institute of Industry Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
Angew Chem Int Ed Engl. 2017 Jun 12;56(25):7088-7092. doi: 10.1002/anie.201700647. Epub 2017 Apr 28.
Protein corona formation was regulated on the surface in vivo by molecular imprinting to enable polymeric nanogels to acquire stealth upon intravenous administration. Albumin, the most abundant protein in blood, was selected as a distinct protein component of protein corona for preparing molecularly imprinted nanogels (MIP-NGs) to form an albumin-rich protein corona. Intravital fluorescence resonance energy transfer imaging of rhodamine-labeled albumin and fluorescein-conjugated MIP-NGs showed that albumin was captured by MIP-NGs immediately after injection, forming an albumin-rich protein corona. MIP-NGs circulated in the blood longer than those of non-albumin-imprinted nanogels, with almost no retention in liver tissue. MIP-NGs also passively accumulated in tumor tissue. These data suggest that this strategy, based on regulation of the protein corona in vivo, may significantly influence the development of drug nanocarriers for cancer therapy.
通过分子印迹在体内调控蛋白质冠形成,使聚合纳米凝胶在静脉给药时获得隐身效果。白蛋白是血液中最丰富的蛋白质,被选为蛋白质冠的独特蛋白质成分,用于制备分子印迹纳米凝胶(MIP-NGs)以形成富含白蛋白的蛋白质冠。吖啶标记白蛋白和荧光素缀合 MIP-NGs 的活体荧光共振能量转移成像表明,白蛋白在注射后立即被 MIP-NGs 捕获,形成富含白蛋白的蛋白质冠。MIP-NGs 在血液中的循环时间长于非白蛋白印迹纳米凝胶,在肝组织中几乎没有保留。MIP-NGs 也被动地在肿瘤组织中积累。这些数据表明,这种基于体内调控蛋白质冠的策略可能会显著影响癌症治疗药物纳米载体的发展。